Translational semantics and infrastructure: Asearch for the emperor's new clothes?

Drug Discovery Today

Volumn 17, Issue 9-10, 2012, Pages 459-468

  Mullane, Kevin ^a   Williams, Michael ^b  

^a Profectus Pharma Consulting   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; FUNDING; HEALTH CARE QUALITY; REVIEW; SEMANTICS; TRANSLATIONAL MEDICINE; TRANSLATIONAL RESEARCH;

ANIMALS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84863394784     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.01.004     Document Type: Review

References (79)

1. M.G. Wokasch Pharmaplasia 2010 Wokasch Consulting, LLC McFarland, WI
2. G. Higgs Where do innovative drugs come from? Drug Discov. Today 16 2011 907 909
3. B.H. Munos, and W.W. Chin How to revive breakthrough innovation in the pharmaceutical industry Sci. Transl. Med. 3 2011 89cm16
4. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 2009 959 968
5. F. Pammolli The productivity crisis in pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 428 438
6. Rockoff, J.D. and Winslow, R. (2011) Drug Makers Refill Parched Pipelines. The Wall Street Journal WSJ 11 July, p. 11
7. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715
8. J. Drews, and S. Ryser Innovation deficit in the pharmaceutical industry Drug Inform. J. 30 1996 97 107
9. N.S. Sung Central challenges facing the national clinical research enterprise JAMA 289 2003 1278 1287
10. S.H. Woolf The meaning of translational research and why it matters JAMA 299 2008 211 213
11. M. Wehling Assessing the translatability of drug projects: what needs to be scored to predict success? Nat. Rev. Drug Discov. 8 2009 541 546
12. F.S. Collins Reengineering translational science: the time is right Sci. Transl. Med. 3 2011 90cm17
13. J.B. Hogenesch, and H.R. Ueda Understanding systems-level properties: timely stories from the study of clocks Nat. Rev. Genet. 12 2011 407 416
14. J. Kaiser National institutes of health. Drug-screening program looking for a home Science 334 2011 299
15. H.H. Dale Progress in autopharmacology: a survey of present knowledge of the chemical regulation of certain functions by natural constituents of tissue John Hopkins Med. J. 53 1933 297 347
16. P.S. Mischel Lost-and found-in translation J. Clin. Invest. 121 2011 3357 3359
17. M. Wehling Drug development in the light of translational science: shine or shade? Drug Discov. Today 16 2011 1076 1083
18. M. Helfand The Methods Work Group of the National CTSA Strategic Goal Committee on Comparative Effectiveness Research A CTSA agenda toadvance methods for comparative effectiveness research Clin. Transl. Sci. 4 2011 188 198
19. S.P. Mankoff Lost in translation: obstacles to translational medicine J. Transl. Med. 2 2004 14
20. J.K. Igelhart Prioritizing comparative-effectiveness research - IOM recommendations N. Engl. J. Med. 361 2009 325 328
21. S. Lewis, and J. Lieberman CATIE and CUtLASS: can we handle the truth? Br. J. Psychiatry 192 2008 161 163
22. M. Williams Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept? Biochem. Pharmacol. 70 2005 1707 1716
23. K. Fiscella Nomenclature in translational research JAMA 299 2008 2148 2149
24. G.A. Fitzgerald Drugs, industry, and academia Science 320 2008 1563
25. G.A. Fitzgerald Anticipating change in drug development: the emerging era of translational medicine and therapeutics Nat. Rev. Drug Discov. 4 2005 815 818
26. P. Kohl, and D. Noble Systems biology and the virtual physiological human Mol. Syst. Biol. 5 2011 292
27. D.F. Horrobin Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat. Rev. Drug Discov. 2 2003 151 154
28. D.L. Braff Promises and challenges in translational research in neuropsychiatry J.E. Barrett, Translational Neuroscience: Applications in Neurology, Psychiatry and Neurodevelopmental Disorders 2012 Cambridge University Press Cambridge, UK 339 358
29. J. Arrowsmith Trial watch: phase II failures: 2008-2010 Nat. Rev. Drug Discov. 10 2011 328 329
30. M. Walker The major impacts of James Black's drug discoveries on medicine and pharmacology Trends Pharmacol. Sci. 32 2011 183 188
31. N.R. Augustine the 2005 'Rising Above the Gathering Storm Committee Rising Above the Gathering Storm Revisited 2010 National Academies Press Washington, D.C.
32. G.P. Pisano, and W.C. Shihm Restoring American competitiveness Harvard Business Rev. 2009 1 13
33. F. Prinz Believe it or not: how much can we relay onpublished data on potential drug targets? Nat. Rev. Drug Discov. 10 2011 712 713
34. F.D. Finkelman Importance of cytokines in murine allergic airway disease and human asthma J. Immunol. 184 2010 1663 1674
35. S.A. Hinke Inverse vaccination with islet autoantigens to halt progression of autoimmune diabetes Drug Dev. Res. 72 2011 788 804
36. V.E. O'Collins 1,026 Experimental treatments in acute stroke Ann. Neurol. 59 2006 467 477
37. E. Nestler, and S.E. Hyman Animal models of neuropsychiatric disorders Nat. Neurosci. 13 2010 1161 1169
38. H.B. van der Worp Can animal models of disease reliably inform human studies? PLoS Med. 7 2010 e1000245
39. K.K. Kopec Target identification and validation in drug discovery: the role of proteomics Biochem. Pharmacol. 69 2005 1133 1139
40. B. Alberts Editorial expression of concern Science 330 2010 912
41. Naik, G. (2011) Mistakes in scientific studies surge. Wall St. Journal, 10 August A1/A12
42. M. Williams Qualitative pharmacology in a quantitative world: diminishing value in the drug discovery process Curr. Opin. Pharmacol. 11 2011 496 500
43. M. Lindner Clinical attrition due to biased preclinical assessments of potential efficacy Pharmacol. Ther. 115 2007 148 175
44. Lehrer, J. (2010) Annals of Science. The Truth Wears Off. New Yorker, 13 December, 2010
45. J.P.A. Ioannidis Excess significance bias in the literature on brain volume abnormalities Arch. Gen. Psychiatr. 68 2011 773 780
46. J.A. Couzin-Frankel Trying to reset the clock on Type I diabetes Science 333 2011 819 821
47. K.M. Mullane Asthma translational medicine: report card Biochem. Pharmacol. 82 2011 567 585
48. J. Cummings What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease? Biol. Psychiatr. 68 2010 876 878
49. D.M. Holtzman Alzheimer's disease: the challenge of the second century Science Transl. Med. 3 2011 77sr1
50. D.J. Selkoe Resolving controversies on the path to Alzheimer's therapeutics Nat. Med. 27 2011 1060 1065
51. H.-G. Lee Amyloid-β in Alzheimer disease: the null versus the alternate hypotheses J. Pharmacol. Exp. Ther. 321 2007 823 829
52. Popper, K. (1959) The Logic of Scientific Discovery, Routledge, London reprinted 1992
53. D.G. Trist Scientific process, pharmacology and drug discovery Curr. Opin. Pharmacol. 11 2011 528 533
54. R.A. Firestone Lessons from 54 years of pharmaceutical research Nat. Rev. Drug Discov. 10 2011 963
55. J.P.A. Ioannidis Whymost published research findings are false PLoS Med. 2 2005 e124
56. D. Fanelli How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data PLoS ONE 4 2009 e5738
57. The Economist (2011) 10th, September 10th, 2011, Misconduct in science. An array of errors
58. G. Vogel Psychologist accused of fraud on an 'astonishing scale' Science 334 2011 579
59. Borrell, B. (2009) A medical Madoff: Anesthesiologist faked data in 21studies. Sci. Am., 10 March, 2009
60. J.A. Weisbach, and W.H. Moos Diagnosing the decline of major pharmaceutical research laboratories: aprescription for drug companies Drug Dev. Res. 34 1995 243 259
61. P. Cuatrecasas Drug discovery in jeopardy J. Clin. Invest. 116 2006 2837 2842
62. J. LaMattina The impact of mergers on pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 559 560
63. P. Elkind Inside Pfizer's palace coup Fortune 2011 164
64. A. Mullard Reliability of 'new drug target' claims called into question Nat. Rev. Drug Discov. 10 2011 643 644
65. R.L. Woosley, and J. Cossman Drug development and the FDA's Critical Path Initiative Clin. Pharmacol. Ther. 81 2007 129 133
66. F. Ullman, and R. Boutellier Drug discovery: are productivity metrics inhibiting motivation and creativity? Drug Discov. Today 37 2008 997 1001
67. R. Macarron Impact of high-throughput screening inbiomedical research Nat. Rev. Drug Discov. 10 2011 188 195
68. M. Williams Productivity short falls in drug discovery: contributions from the preclinical sciences? J. Pharmacol. Exp. Ther. 336 2011 3 8
69. Y.L. Bennani Drug discovery in the next decade: innovation needed ASAP Drug Discov. Today 16 2011 779 792
70. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat. Rev. Drug Discov. 10 2011 507 519
71. International Human Genome Sequencing Consortium Finishing the euchromatic sequence of the human genome Nature 431 2004 931 945
72. T.A. Manolio Genomewide association studies and assessment of the risk of disease N. Engl. J. Med. 363 2010 166 176
73. F.S. Collins A vision for the future of genomics research Nature 422 2003 835 847
74. J.P. Evans Deflating the genomic bubble Science 331 2011 861 862
75. C. Biémont A brief history of the status of transposable elements: from junk DNA to major players in evolution Genetics 186 2010 1085 1093
76. D.C. Wallace Mitochondrial diseases in man and mouse Science 283 1999 1482 1488
77. S. Frye US academic drug discovery Nat. Rev. Drug Discov. 10 2011 409 410
78. H. Kubinyi Drug research: Myths, hype and reality Nat. Rev. Drug Discov. 2 2003 665 668
79. I.S. Kohane [Mis]treating the pharmacogenetic incidentalome Nat. Rev. Drug Discov. 11 2012 89 90